Lymphocyte count and characteristics of the IGH gene in subjects with spontaneous CLL regression
| . | B-cell count, ×109/L . | CLL count, ×109/L . | % CLL cells of B cells . | % CLL cells of lymphocytes . | IGH gene usage . | IGHV % homology to germline . | T-cell count, ×109/L . | CD4+ T-cell count, ×109/L . | CD8+ T-cell count, ×109/L . | NK-cell count, ×109/L . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VH . | DH . | JH . | ||||||||||
| CLL01 | 1.0 | 0.9 | 92.0 | 28.8 | 3-30 | 4-17 | 4 | 95.5 | 1.9 | 1.2 | 0.7 | 0.3 |
| CLL02 | 2.1 | 2.1 | 99.0 | 63.6 | 3-53 | 2-21 | 4 | 93.7 | 1.0 | 0.6 | 0.4 | 0.2 |
| CLL03 | 0.4 | 0.4 | 91.6 | 23.8 | 1-69 | 5-12 | 3 | 91.7 | 0.8 | 0.4 | 0.4 | 0.3 |
| CLL04 | 0.5 | 0.5 | 91.5 | 28.0 | 3-48 | 5-18 | 1 | 95.5 | 1.0 | 0.7 | 0.3 | 0.2 |
| CLL05 | 1.4 | 1.0 | 71.6 | 38.5 | 2-5 | 2-15 | 4 | 96.3 | 1.1 | 0.5 | 0.4 | 0.1 |
| CLL06 | 1.7 | 1.7 | 98.8 | 48.0 | 4-34 | 6-13 | 4 | 87.9 | 1.7 | 0.6 | 1.0 | 0.1 |
| CLL07 | 2.2 | 2.2 | 98.0 | 59.9 | 3-23 | 6-19 | 3 | 93.1 | 1.2 | 0.7 | 0.5 | 0.2 |
| CLL08 | — | — | 86.1 | — | 3-15 | 1-1 | 3 | 89.1 | — | — | — | — |
| CLL09 | 2.0 | 1.8 | 92.2 | 58.0 | 4-39 | 2-8 | 5 | 91.8 | 0.7 | 0.5 | 0.2 | 0.4 |
| CLL10 | 1.3 | 1.2 | 92.5 | 37.6 | 3-13 | 3-16 | 6 | 92.6 | 1.8 | 1.0 | 0.7 | 0.1 |
| CLL11 | 0.7 | 0.7 | 98.3 | 57.3 | 4-4 | 3-22 | 4 | 94.8 | 0.4 | 0.3 | 0.2 | 0.1 |
| CLL12 | 1.6 | 1.2 | 75.0 | 21.4 | 3-30 | 3-10 | 4 | 91.7 | 3.9 | 1.0 | 2.7 | 0.1 |
| CLL13 | 5.3 | 5.3 | 99.8 | 46.8 | 3-74 | 2-21 | 5 | 88.9 | 4.4 | 3.6 | 0.6 | 1.6 |
| CLL14 | 6.6 | 6.5 | 98.2 | 76.2 | 3-23 | 6-6 | 2 | 89.9 | 1.6 | 0.8 | 0.6 | 0.3 |
| CLL15 | 3.4 | 3.4 | 99.2 | 61.3 | 3-30 | 1-1 | 3 | 97.6 | 1.8 | 0.9 | 0.9 | 0.3 |
| CLL16 | 6.1 | 5.9 | 96.4 | 84.0 | 3-23 | 4-17 | 5 | 92.7 | 0.6 | 0.3 | 0.3 | 0.3 |
| CLL18 | 1.9 | 1.8 | 92.4 | 58.5 | 3-23 | 6-19 | 5 | 93.1 | 0.9 | 0.4 | 0.4 | 0.3 |
| CLL19 | 6.7 | 6.2 | 92.0 | 80.0 | 4-34 | 5-18 | 6 | 95.1 | 0.7 | 0.4 | 0.3 | 0.3 |
| CLL20 | — | — | — | — | 4-34 | 6-19 | 3 | 94.7 | — | — | — | — |
| . | B-cell count, ×109/L . | CLL count, ×109/L . | % CLL cells of B cells . | % CLL cells of lymphocytes . | IGH gene usage . | IGHV % homology to germline . | T-cell count, ×109/L . | CD4+ T-cell count, ×109/L . | CD8+ T-cell count, ×109/L . | NK-cell count, ×109/L . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VH . | DH . | JH . | ||||||||||
| CLL01 | 1.0 | 0.9 | 92.0 | 28.8 | 3-30 | 4-17 | 4 | 95.5 | 1.9 | 1.2 | 0.7 | 0.3 |
| CLL02 | 2.1 | 2.1 | 99.0 | 63.6 | 3-53 | 2-21 | 4 | 93.7 | 1.0 | 0.6 | 0.4 | 0.2 |
| CLL03 | 0.4 | 0.4 | 91.6 | 23.8 | 1-69 | 5-12 | 3 | 91.7 | 0.8 | 0.4 | 0.4 | 0.3 |
| CLL04 | 0.5 | 0.5 | 91.5 | 28.0 | 3-48 | 5-18 | 1 | 95.5 | 1.0 | 0.7 | 0.3 | 0.2 |
| CLL05 | 1.4 | 1.0 | 71.6 | 38.5 | 2-5 | 2-15 | 4 | 96.3 | 1.1 | 0.5 | 0.4 | 0.1 |
| CLL06 | 1.7 | 1.7 | 98.8 | 48.0 | 4-34 | 6-13 | 4 | 87.9 | 1.7 | 0.6 | 1.0 | 0.1 |
| CLL07 | 2.2 | 2.2 | 98.0 | 59.9 | 3-23 | 6-19 | 3 | 93.1 | 1.2 | 0.7 | 0.5 | 0.2 |
| CLL08 | — | — | 86.1 | — | 3-15 | 1-1 | 3 | 89.1 | — | — | — | — |
| CLL09 | 2.0 | 1.8 | 92.2 | 58.0 | 4-39 | 2-8 | 5 | 91.8 | 0.7 | 0.5 | 0.2 | 0.4 |
| CLL10 | 1.3 | 1.2 | 92.5 | 37.6 | 3-13 | 3-16 | 6 | 92.6 | 1.8 | 1.0 | 0.7 | 0.1 |
| CLL11 | 0.7 | 0.7 | 98.3 | 57.3 | 4-4 | 3-22 | 4 | 94.8 | 0.4 | 0.3 | 0.2 | 0.1 |
| CLL12 | 1.6 | 1.2 | 75.0 | 21.4 | 3-30 | 3-10 | 4 | 91.7 | 3.9 | 1.0 | 2.7 | 0.1 |
| CLL13 | 5.3 | 5.3 | 99.8 | 46.8 | 3-74 | 2-21 | 5 | 88.9 | 4.4 | 3.6 | 0.6 | 1.6 |
| CLL14 | 6.6 | 6.5 | 98.2 | 76.2 | 3-23 | 6-6 | 2 | 89.9 | 1.6 | 0.8 | 0.6 | 0.3 |
| CLL15 | 3.4 | 3.4 | 99.2 | 61.3 | 3-30 | 1-1 | 3 | 97.6 | 1.8 | 0.9 | 0.9 | 0.3 |
| CLL16 | 6.1 | 5.9 | 96.4 | 84.0 | 3-23 | 4-17 | 5 | 92.7 | 0.6 | 0.3 | 0.3 | 0.3 |
| CLL18 | 1.9 | 1.8 | 92.4 | 58.5 | 3-23 | 6-19 | 5 | 93.1 | 0.9 | 0.4 | 0.4 | 0.3 |
| CLL19 | 6.7 | 6.2 | 92.0 | 80.0 | 4-34 | 5-18 | 6 | 95.1 | 0.7 | 0.4 | 0.3 | 0.3 |
| CLL20 | — | — | — | — | 4-34 | 6-19 | 3 | 94.7 | — | — | — | — |
B-cell, CD4+ T-cell, CD8+ T-cell, and NK-cell count were derived from the ALC taking into consideration the proportion of lymphocytes that were CD19+, CD3+CD4+, CD3+CD8+, and CD16+CD3−CD4−, respectively. The CLL count was derived from the B-cell count taking into account of the proportion of CLL cells in the B-lymphocyte population, determined using the methodology illustrated in Figure 2A. IGH sequencing was performed on DNA from sorted CLL cells using IGHV leader and IGHJ consensus primers. Gene usage and percent homology to the germline IGHV sequence was determined using the international immunogenetics information (IGMT) platform.
—, data not available/applicable.